Anacor inks $160M acne drug pact with Medicis

Anacor Pharmaceuticals will pocket $7 million and gain the potential to garner up to $153 million more under its pact to work with Medicis Pharmaceutical on boron-based small molecule therapies for acne. Anacor will use its boron chemistry platform to discover and initially develop acne drugs. Medicis will be responsible for further development and commercialization of the licensed products on a worldwide basis. "With our technology and Medicis' expertise in developing and commercializing pharmaceuticals, we hope this collaboration will result in innovative products to help the patients who suffer from this condition," said Anacor CEO David Perry. Anacor release